| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bluejay Diagnostics, Inc.$1.45
+0.05 (+3.57%)
F 9Pipeline Score MedTech · Clinical
Market Cap
1.99 M
EPS
-14.02
P/E Ratio
-
Value Trade
4.55 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
811.84 K
Operating CF
-1.59 M
Total Assets
5.60 M
Total Liabilities
1.42 M
Equity
4.18 M
D/E Ratio
12,345
11.63 %
Week
-4 %
1 Month
-4.48 %
3 Month
-62.79 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
3.68 M
Monthly Burn
530.00 K
Runway
4.8 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
2.02 M
52 Week Range
1.62 - 16.68
% held by Insiders
9.5 %
% held by Institutions
5.69 %
Enterprise Value
-1.59 M
Total Shares
2.61 M
Short %
19.36 %
Float Shares
2.35 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F9
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 7%
Micro Cap (rank 849 of 912)
Percentile RankBluejay Diagnostics, Inc. has significant pipeline risk (9/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Symphony IL-6 Test | sepsis | — | 2026-03-12 | IL-6 measured in the emergency department may be associated with subsequent organ dysfunction in patients with sepsis and septic shock. Read More | Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting Read More | |
Symphony IL-6 Test | sepsis | — | 2026-03-12 | IL-6 measured in the emergency department may be associated with subsequent organ dysfunction in patients with sepsis and septic shock. Read More | Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting Read More | |
Symphony IL-6 Test | sepsis | — | 2026-03-12 | IL-6 measured in the emergency department may be associated with subsequent organ dysfunction in patients with sepsis and septic shock. Read More | Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BJDX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BJDX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BJDX▲ +9%on this news
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Bluejay Diagnostics has successfully closed a private placement raising $23.7 million, which includes $8.5 million upfront and potential additional proceeds of $15.2 million from warrants. The net proceeds are expected to extend the company's cash runway into the first quarter of 2027, aiding in FDA submission and commercialization efforts. The offering was facilitated by H.C. Wainwright & Co.
Read more →BJDX▼ -15.6%on this news
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bluejay Diagnostics has announced a private placement expected to raise $8.5 million, with potential additional proceeds of approximately $15.1 million from warrants. The net proceeds are anticipated to extend the company's cash runway into the first quarter of 2027, supporting their FDA submission and other research activities. The offering is set to close on June 3, 2026, pending customary conditions.
Read more →BJDX▲ +100%on this newsshared move
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
Bluejay Diagnostics has formed a strategic partnership with Argonaut Manufacturing Services to advance its Symphony platform. This collaboration aims to establish scalable U.S.-based manufacturing capabilities, enhancing supply chain resilience and reducing reliance on overseas production. The partnership is expected to support Bluejay's clinical development and commercialization efforts for its near-patient diagnostic solutions.
Read more →BJDXBluejay Diagnostics Provides First Quarter 2026 Corporate Update
Bluejay Diagnostics provided an update on its progress in Q1 2026, focusing on advancements in the Symphony IL-6 test for sepsis. The company reported a successful enrollment of around 680 patients in its SYMON-II pivotal clinical study, aiming for a total of 750 participants. Additionally, Bluejay has resolved manufacturing issues and is preparing for regulatory submissions. With financial management in focus, Bluejay is navigating its objectives towards future commercialization opportunities.
Read more →BJDXBluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
Bluejay Diagnostics has successfully enrolled 624 patients in its SYMON-II pivotal clinical trial, which aims to evaluate the Symphony™ platform for IL-6 testing in critical care settings. The trial is nearing its target enrollment of 750 patients, expected to be completed in the next 2 to 3 months. The study's criteria have not significantly excluded patients, indicating effective recruitment.
Read more →BJDXBluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
Bluejay Diagnostics announced that its abstract on the Symphony IL-6 Test has been accepted for presentation at the 2026 SAEM Annual Meeting. The study evaluates IL-6 levels in sepsis patients and their correlation with organ dysfunction. This research could enhance the understanding of IL-6 as a biomarker for critical care conditions.
Read more →BJDXBluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
Bluejay Diagnostics provided a corporate update regarding its Symphony platform and 2026 strategic outlook. The company confirmed progress in its SYMON II clinical study and ongoing manufacturing readiness efforts, positioning itself for future commercial production. Bluejay is focused on enhancing manufacturing and supply chain robustness while also seeking to raise additional capital as part of its growth strategy. Despite some financial challenges in the past year, the company remains optimistic about its future contributions to patient care in critical settings.
Read more →BJDXBluejay Diagnostics Announces All Prefunded Warrants Now Exercised
Bluejay Diagnostics announced that all prefunded warrants from its October 2025 private placement have been fully exercised as of February 19, 2026. The company now has around 972,000 shares outstanding and additional cash exercisable warrants for approximately 1.5 million shares. However, the Symphony System, aimed at improving sepsis diagnosis, still requires FDA regulatory clearance.
Read more →BJDXBluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
Bluejay Diagnostics has enrolled 545 patients in its SYMON™ II study, surpassing its target of 750. The company is advancing its manufacturing readiness and technology transfer initiatives into 2026. This progress is expected to strengthen regulatory positioning and support future partnerships as Bluejay transitions towards data analysis and commercialization.
Read more →BJDXBluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Bluejay Diagnostics has announced a 1-for-4 reverse stock split, effective January 29, 2026. This action will reduce the number of outstanding shares from approximately 2.83 million to about 708,533. The company aims to enhance its stock's marketability while maintaining its existing trading symbol on Nasdaq. Shareholders will receive cash payments for any fractional shares.
Read more →BJDXBluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production
Bluejay Diagnostics has successfully completed the commercial-scale production of polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6). These antibodies meet internal performance criteria and are intended for use in the Symphony cartridge manufacturing process. The company has enough inventory to support the production of over nine million cartridges, although the Symphony system is still under development and requires regulatory approval.
Read more →BJDXBluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships
Bluejay Diagnostics, Inc. has reported its financial results for Q3 2025, emphasizing progress in its clinical and operational initiatives. The company aims to redefine sepsis management through its Symphony platform, which is designed for rapid near-patient testing. However, the Symphony System is still awaiting FDA regulatory clearance before it can be marketed in the U.S.
Read more →BJDX▼ -10.7%on this news
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Bluejay Diagnostics has successfully closed a private placement, raising $4.5 million through the sale of 2.25 million shares and Series F warrants. The funds will be used for FDA approval processes and R&D activities. The Series F warrants have an exercise price of $1.75 and are immediately exercisable, expiring in five and a half years.
Read more →BJDX▲ +75.4%on this newsshared move
Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform
Bluejay Diagnostics has amended its agreements with SanyoSeiko to enhance the commercialization of its Symphony platform, a near-patient testing system for sepsis management. The partnership will allow SanyoSeiko to provide comprehensive manufacturing support, including hardware and software updates, and quality control. This collaboration aims to secure high-quality production capacity and facilitate broader clinical validation.
Read more →BJDX▲ +75.4%on this newsshared move
Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bluejay Diagnostics has announced a successful agreement for a private placement of 2,250,000 shares of common stock and Series F warrants totaling $4.5 million. The proceeds from this offering will be directed towards obtaining FDA approval and furthering research and development efforts. Closing of the placement is expected shortly, but the issued securities will not be registered under current securities laws, imposing restrictions on their sale.
Read more →BJDX▲ +75.4%on this newsshared move
Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform Acton, MA, USA and Yamanashi, Japan
Bluejay Diagnostics and SanyoSeiko have expanded their strategic partnership to enhance the commercialization of the Symphony platform, which focuses on rapid near-patient testing for key biomarkers in critical care. The amended agreement allows SanyoSeiko to take on a larger role in manufacturing, including the management of raw materials and fulfillment processes. Bluejay's CEO emphasized that this partnership will improve supply chain resilience and production capacity, while SanyoSeiko's CEO expressed excitement about the partnership's potential impact on global healthcare diagnostics. The Symphony platform aims to provide accurate results for sepsis management, pending regulatory approval.
Read more →BJDXBluejay Diagnostics Provides Second Quarter Business and Corporate Update
Bluejay Diagnostics reported its financial results for Q2 2025 and highlighted advancements in its Symphony IL-6 test program. The company is making significant progress with the SYMON-II clinical studies, which aim to validate the predictive value of the Symphony IL-6 test in sepsis care. Bluejay is also working on updated licensing and manufacturing partnerships to enhance scalability and is actively seeking strategic partners for support.
Read more →BJDXBluejay Diagnostics Provides Mid-Year Business and Corporate Update
Bluejay Diagnostics has provided a mid-year update revealing the initiation of the pivotal SYMON-II clinical study for its Symphony IL-6 test aimed at improving sepsis patient outcomes. The company plans to submit a 510(k) application to the FDA by late 2027 following regulatory interactions. Financially, Bluejay reported a cash position of $5.7 million but has also faced significant losses and recently downsized its workforce to conserve cash resources. The upcoming annual meeting will address board reductions and proposals for reverse stock splits to meet Nasdaq listing requirements.
Read more →BJDXBluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting
Bluejay Diagnostics announced the acceptance of an abstract for the Symphony IL-6 Test at the 2025 SAEM Annual Meeting. The presentation will discuss findings from the SYMON-I study, which evaluated IL-6 as a prognostic marker in sepsis patients. The results suggest that IL-6 may help predict mortality and guide treatment decisions. The company is also conducting a follow-up study, SYMON-II, to validate these findings.
Read more →BJDX▼ -60.7%on this news
Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds
Bluejay Diagnostics has announced a warrant inducement transaction that will generate approximately $3.7 million in gross proceeds. Existing investors will exercise their warrants to purchase shares at a reduced price, receiving new warrants in return. This move is part of the company's strategy to support its rapid diagnostics development.
Read more →BJDX▲ +112.5%on this newsshared move
IMMEDIATE RELEASE Date
Bluejay Diagnostics announced a transaction with existing institutional investors to exercise warrants for common stock at a reduced price, generating approximately $3.7 million in gross proceeds. The investors will receive new warrants, which are immediately exercisable at the same price, retaining their investment confidence. The funds are likely to support the development of the Symphony platform, aimed at improving diagnostics and patient outcomes in critical care. This financial maneuver highlights the company's ongoing commitment to enhancing its capabilities in the medical diagnostics sector.
Read more →BJDXBluejay Diagnostics Announces Reverse Stock Split
Bluejay Diagnostics, Inc. has announced a reverse stock split of its common shares at a ratio of 1-for-50. This will take effect on November 18, 2024, reducing the number of outstanding shares significantly. The reverse stock split is aimed at improving the stock's marketability while all stockholders will be treated equally. However, the announcement raises concerns about the company's cash position and the uncertainties surrounding regulatory approval for their diagnostic products.
Read more →BJDX▼ -6.8%on this news
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
Bluejay Diagnostics, Inc. has successfully closed an underwritten public offering, securing approximately $8.75 million in gross proceeds. The offering consisted of Common Units and Prefunded Units, providing shareholders opportunities to acquire common stock through various warrants. Proceeds will be allocated towards repaying outstanding debt, advancing FDA approval processes, and supporting research and development activities. The offering was underwritten by Aegis Capital Corp., and the securities were registered with the SEC.
Read more →BJDXBluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering
Bluejay Diagnostics has announced a pricing of its underwritten public offering expected to generate approximately $8.75 million before expenses. The base offering consists of over 5 million Common Units and Prefunded Units, each providing various warrants for future stock purchases. The net proceeds will be used to repay existing debt and to support FDA approval processes. The transaction is expected to close on June 28, 2024, pending customary conditions.
Read more →BJDXSYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
Bluejay Diagnostics, Inc. announced positive results from the SYMON-I study, which explored the role of interleukin-6 (IL-6) in sepsis patients. The study indicates that IL-6 levels upon ICU admission may help predict mortality risk. This multicenter pilot study adds valuable insights into sepsis management.
Read more →BJDXBluejay Diagnostics Announces Closing of $3.5 Million Public Offering
Bluejay Diagnostics announced the successful closing of a public offering, raising approximately $3.5 million through the issuance of common stock and warrants. The proceeds will be allocated towards obtaining FDA approval for its Symphony system, which is designed for rapid diagnostic testing in critical care settings. The company aims to enhance patient outcomes with its innovative technologies and plans to use the funds for further research and general working capital.
Read more →BJDXBluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
Bluejay Diagnostics, Inc. has announced the pricing of a public offering of 2,692,308 shares at a combined price of $1.30 per share, aiming to raise $3.5 million. The proceeds will fund activities related to obtaining FDA approval for its rapid diagnostic platform and other research and development efforts. The offering is expected to close on or about January 2, 2024, subject to customary closing conditions. H.C. Wainwright & Co. is the exclusive placement agent for the offering.
Read more →BJDXBluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)
Bluejay Diagnostics, Inc. announced the initiation of a multicenter clinical study to evaluate their Symphony IL-6 test for sepsis patients, known as the SYMON study. This study aims to establish IL-6 concentrations that predict 28-day mortality in affected patients. Results from the Symphony System, which provides rapid test results directly from whole blood, have shown promising potential to aid in the management of sepsis. Dr. Mark Feinberg and CEO Neil Dey highlighted the importance of this advancement and its potential competitive advantage as the company moves closer to commercialization.
Read more →BJDXBluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
Bluejay Diagnostics, Inc. reported its financial results for Q3 2023, highlighting a significant reduction in royalty payments following a renegotiated licensing agreement with Toray Industries. The company is focused on its Symphony IL-6 testing platform, which aims to improve sepsis care by enabling faster diagnostic results. Despite ongoing net losses, Bluejay aims to submit for FDA regulatory approval in the first half of 2024. The company anticipates needing additional capital to support operations in the coming year.
Read more →BJDXBluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Bluejay Diagnostics, Inc. has announced a definitive agreement for a registered direct offering to sell 216,000 shares of common stock at a price of $7.365 per share, aiming to raise approximately $1.59 million. The gross proceeds will support FDA approvals, clinical studies, and general working capital. The offerings are set to close on or about August 28, 2023, pending customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for these transactions.
Read more →BJDXBluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results
Bluejay Diagnostics, Inc. provided an update on its clinical activities and financial performance for the second quarter of 2023. The company is advancing its Symphony IL-6 test, aimed at improving risk stratification for sepsis patients, with a 510(k) FDA submission anticipated by mid-2024. While Bluejay is managing its cash burn and targeting reputable institutions for studies, it reported a net loss of $5.4 million and a reduction in cash and equivalents since December 2022.
Read more →BJDXBluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Bluejay Diagnostics, Inc. announced on August 10, 2023, that it has regained compliance with Nasdaq's minimum bid price requirement after its stock closed above $1.00 for ten consecutive business days. This follows a reverse stock split executed on July 24, 2023, which was necessary after the company previously received a notification for non-compliance in October 2022. The company's Symphony System, which provides rapid near-patient testing, is designed to enhance patient triage and monitoring. The matter of minimum bid price deficiency is now considered resolved according to Nasdaq regulations.
Read more →BJDXBluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy
Bluejay Diagnostics announced an updated regulatory strategy for its Symphony IL-6 biomarker test, shifting focus to risk stratification for hospitalized sepsis patients. The new strategy, based on FDA feedback, expands trial inclusion criteria to enhance enrollment and maintain an anticipated regulatory submission timeline for the first half of 2024. The Symphony IL-6 test aims to provide rapid and quantitative results to improve patient outcomes in critical care settings, particularly for sepsis management.
Read more →BJDXBluejay Diagnostics Reports First Quarter 2023 Financial Results
Bluejay Diagnostics, Inc. has reported its financial results for the first quarter of 2023, showing a decrease in cash reserves, which dropped from $10.1 million to $6.8 million. The company's net loss for the quarter was $2.5 million, an increase compared to the previous year's loss of $2.0 million. Despite these challenges, Bluejay remains committed to its Symphony platform, focusing efforts on aligning its clinical study with FDA feedback to enhance its regulatory approval pathway.
Read more →BJDXBluejay Diagnostics Reports 2022 Financial Results
Bluejay Diagnostics reported its financial results for the year ended December 31, 2022, highlighting both achievements and challenges. The company made significant strides in developing its Symphony System, a rapid testing platform, but faced delays in its FDA submission, now expected in the first half of 2024. Notably, Bluejay's net loss increased substantially to $9.3 million, and its cash reserves decreased significantly over the year, stressing the need for additional funding. Despite these challenges, the company aims to cultivate strategic partnerships to bolster its market entry and expand the reach of its IL-6 test.
Read more →BJDXBluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America
Bluejay Diagnostics, Inc. has announced a collaboration with Blood Centers of America to develop commercial relationships utilizing the SymphonyTM Platform in blood and hospital markets. As part of the agreement, Bluejay will serve as a strategic partner and gain access to BCA's members, enabling enhanced patient care. The partnership aims to address urgent needs in critical care settings and explore innovative solutions to support the sustainability of the blood supply.
Read more →BJDXBluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results
ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in criti
Read more →BJDXBluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results Acton, Massachusetts
Diagnostics, Inc. Reports Third Quarter 2022 Financial Results Massachusetts, October 25, 2022 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX) ("Bluejay" or the "Company"), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Sym
Read more →BJDXBluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
ACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced tha
Read more →BJDXBluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure
ACTON, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced t
Read more →BJDXBluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results
ACTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced f
Read more →BJDXIMMEDIATE RELEASE Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results Acton, Massachusetts
Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results Acton, Massachusetts, July 26, 2022 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests f
Read more →BJDXBluejay Completes Planned Clinical Studies for Symphony IL-6 Test
ACTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced
Read more →BJDXBluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test
ACTON, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced
Read more →BJDXBluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results
ACTON, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, tod
Read more →BJDXIMMEDIATE RELEASE Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results Acton, Massachusetts
Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results Acton, Massachusetts, April 20, 2022 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX) ("Bluejay", "the Company"), a pre-revenue medical diagnostics company focused on developing cost-effective, rapid, near-patie
Read more →BJDXBluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance
ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression,
Read more →BJDXBluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer
ACTON, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression,
Read more →BJDXIMMEDIATE RELEASE Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer Acton, Massachusetts.
Diagnostics Appoints Kenneth Fisher as Chief Financial Officer Massachusetts. March 24, 2022 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX) ("Bluejay", "the Company") a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products fo
Read more →BJDXBluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Testing program underway for lead product candidate, the Symphony IL-6 Test, in support of an FDA Marketing Application, planned for Q3 2022 2021 ended with approximately $19 million in cash expected to fund operations beyond the date of our anticipated regulatory approval and i
Read more →BJDXIMMEDIATE RELEASE Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Testing program underway for lead product candidate, the Symphony IL-6 Test, in suppor
Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update program underway for lead product candidate, the Symphony IL-6 Test, in support of an FDA Marketing Application, planned for Q3 2022 ended with approximately $19 million
Read more →BJDXBluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA
ACTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, t
Read more →BJDXBluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care
ACTON, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease
Read more →BJDXBluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor
ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, t
Read more →BJDXBluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results
IL-6 test for sepsis triage on Track for January 2022 FDA Pre-Submission Filing Expanded Testing Program Planned for Q1-Q3 2022 Raised $21.6 million Gross Proceeds in an Upsized IPO ACTON, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Blue
Read more →BJDXBluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering
ACTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage, diagnosis and monitoring of disease pro
Read more →Competitive Position
How BJDX ranks across every disease it competes inCompetitive Position is a premium feature
See how BJDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial